RIO DE JANEIRO, BRAZIL - Chinese Sinovac Biotech's CoronaVac, the Covid-19 vaccine filled in Brazil by the Butantan Institute, is safe and induces immune response in adolescents and children aged 3 to 17, showed a study published on Monday, June 28.
According to Butantan, the study's findings published by The Lancet were the result of phase 1 and 2 clinical trials with 552 participants between October and December 2020 conducted in the Chinese province of Hebei.
The study was conducted by Sinovac in partnership with Chinese institutions.
The neutralizing antibody seroconversion rate, which indicates the production of antibodies . . .